Literature DB >> 19183898

Production of recombinant proteins in suspension-cultured plant cells.

Carole Plasson1, Rémy Michel, David Lienard, Claude Saint-Jore-Dupas, Christophe Sourrouille, Ghislaine Grenier de March, Véronique Gomord.   

Abstract

Plants have emerged in the past decade as a suitable alternative to the current production systems for recombinant pharmaceutical proteins and, today their potential for low-cost production of high quality, much safer and biologically active mammalian proteins is largely documented. Among various plant expression systems being explored, genetically modified suspension-cultured plant cells offer a promising system for production of biopharmaceuticals. Indeed, when compared to other plant-based production platforms that have been explored, suspension-cultured plant cells have the advantage of being totally devoid of problems associated with the vagaries of weather, pest, soil and gene flow in the environment. Because of short growth cycles, the timescale needed for the production of recombinant proteins in plant cell culture can be counted in days or weeks after transformation compared to months needed for the production in transgenic plants. Moreover, recovery and purification of recombinant proteins from plant biomass is an expensive and technically challenging business that may amount to 80-94% of the final product cost. One additional advantage of plant cell culture is that the recombinant protein fused with a signal sequence can be expressed and secreted into the culture medium, and therefore recovered and purified in the absence of large quantities of contaminating proteins. Consequently, the downstream processing of proteins extracted from plant cell culture medium is less expensive, which may/does balance the higher costs of fermentation. When needed for clinical use, recombinant proteins are easily produced in suspension-cultured plant cells under certified, controllable and sterile conditions that offer improved safety and provide advantages for good manufacturing practices and regulatory compliance. In this chapter, we present basic protocols for rapid generation of transgenic suspension-cultured cells of Nicotiana tabacum, Oriza sativa and Arabidopis thaliana. These systems are powerful tools for plant-made pharmaceuticals production in highly controlled conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183898     DOI: 10.1007/978-1-59745-407-0_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Enhanced heterologous expression of biologically active human granulocyte colony stimulating factor in transgenic tobacco BY-2 cells by localization to endoplasmic reticulum.

Authors:  Nisha R Nair; M Chidambareswaren; S Manjula
Journal:  Mol Biotechnol       Date:  2014-09       Impact factor: 2.695

2.  On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.

Authors:  Jianfeng Xu; Ningning Zhang
Journal:  Pharm Bioprocess       Date:  2014-12-01

3.  Development of an optimized tetracycline-inducible expression system to increase the accumulation of interleukin-10 in tobacco BY-2 suspension cells.

Authors:  Luisa Bortesi; Thomas Rademacher; Andreas Schiermeyer; Flora Schuster; Mario Pezzotti; Stefan Schillberg
Journal:  BMC Biotechnol       Date:  2012-07-11       Impact factor: 2.563

Review 4.  Comparison of Yeasts as Hosts for Recombinant Protein Production.

Authors:  Antonio Milton Vieira Gomes; Talita Souza Carmo; Lucas Silva Carvalho; Frederico Mendonça Bahia; Nádia Skorupa Parachin
Journal:  Microorganisms       Date:  2018-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.